Processing

Please wait...

Settings

Settings

Goto Application

1. WO2001055196 - A NOVEL POLYPEPTIDE - HUMAN CORTICOLIBERIN 26 AND THE POLYNUCLEOTIDE ENCODING THE SAME

Publication Number WO/2001/055196
Publication Date 02.08.2001
International Application No. PCT/CN2001/000089
International Filing Date 21.01.2001
Chapter 2 Demand Filed 20.08.2001
IPC
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
CPC
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Applicants
  • BIODOOR GENE TECHNOLOGY LTD. SHANGHAI [CN]/[CN] (AllExceptUS)
  • MAO, Yumin [CN]/[CN] (UsOnly)
  • XIE, Yi [CN]/[CN] (UsOnly)
Inventors
  • MAO, Yumin
  • XIE, Yi
Agents
  • WATSON & BAND LAW OFFICES
Priority Data
00 1 11617.728.01.2000CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) A NOVEL POLYPEPTIDE - HUMAN CORTICOLIBERIN 26 AND THE POLYNUCLEOTIDE ENCODING THE SAME
(FR) NOUVEAU POLYPEPTIDE, CORTICOLIBERINE HUMAINE 26, ET POLYNUCLEOTIDE CODANT POUR CE POLYPEPTIDE
Abstract
(EN)
The present invention discloses a new polypeptide - human corticoliberin 26, the polynucleotide encoding the same, as well as a method of producing said polypeptide by DNA recombinant techniques. The present invention also discloses methods of using the polypeptide in treatment of various diseases, such as malignant tumor, blood diseases, HIV infection, immunological diseases and a wide variety of inflammations. The invention also discloses an antagonist against the polypeptide and the therapeutic use thereof. Also disclosed is the use of such polynucleotide coding for the new human corticoliberin 26.
(FR)
L'invention concerne un nouveau polypeptide, une corticolibérine humaine 26, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de l'hémopathie, de l'infection par VIH, de maladies immunitaires et de diverses inflammations. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour la corticolibérine humaine 26.
Also published as
Latest bibliographic data on file with the International Bureau